GMP/GCP compliance failures in the drug product segment are no longer identified as the ‘software not being validated for its intended use’, but rather the deficiencies are now linked to the predicate GMP requirements based on FDA’s stated focus in 2010.
This week, there were two warning letters issued to pharmaceutical firms. But first, we address an EIR associated with AveXis and the second warning letter issued to a firm for failure to comply with the Food Foreign Supplier Verification Program.
Govzilla announces the addition of Jane Wastl as Senior GMP Quality Expert to the Govzilla team.
Yesterday, Dr. Janet Woodcock, FDA Director of the Center for Drug Evaluation and Research, has released a statement regarding the recent recalls of Angiotensin II Receptor Blockers (ARB).
Govzilla announces the addition of Jerry Chapman as Senior GMP Quality Expert to the Govzilla team.
Join President of FOI Services, Marlene Bobka, for an informative 1-hour webinar about all things FOIA. Gain a deeper understanding of the internal workings of FDA and help prevent legal actions, financial penalties and other costly errors at your company.
This week, there were a total of five issued warning letters: three were issued to drug manufacturers, one to a compounding pharmacy, and one to a device manufacturer. The first one issued to Deva Holdings addresses severe penicillin cross-contamination.
GMP expert Barbara W. Unger analyzes the major initiatives put forth in CDER’s Office of Compliance Annual Report for CY2018.
We cover three drug warning letters, one issued to a compounding pharmacy, one device warning letter, and one in the food area that is a ‘first of its kind’.
SEARCH LESS KNOW MORE
The essential tool for compliance, regulatory, and quality professionals
